Published in Philos Trans R Soc Lond B Biol Sci on April 29, 2001
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One (2013) 1.40
Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog (2009) 1.39
Gammaherpesvirus lytic gene expression as characterized by DNA array. J Virol (2002) 1.33
Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J (2005) 1.28
Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog (2010) 1.27
Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol (2007) 1.18
How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol (2009) 1.13
The KGD motif of Epstein-Barr virus gH/gL is bifunctional, orchestrating infection of B cells and epithelial cells. MBio (2012) 1.12
Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One (2010) 1.10
BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res (2012) 1.10
Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol (2009) 1.10
BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death Differ (2007) 1.07
Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer (2009) 1.07
Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins. J Virol (2002) 1.05
Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology (2011) 1.05
Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency. J Virol (2005) 1.02
The zipper region of Epstein-Barr virus bZIP transcription factor Zta is necessary but not sufficient to direct DNA binding. J Virol (2003) 0.99
The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J Virol (2005) 0.97
Atypical bZIP domain of viral transcription factor contributes to stability of dimer formation and transcriptional function. J Virol (2007) 0.95
Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol (2003) 0.95
The Emerging Role of Nuclear Viral DNA Sensors. J Biol Chem (2015) 0.94
Unexpected structure of Epstein-Barr virus lytic cycle activator Zta. Trends Microbiol (2006) 0.94
The anti-interferon activity of conserved viral dUTPase ORF54 is essential for an effective MHV-68 infection. PLoS Pathog (2011) 0.91
A membrane leucine heptad contributes to trafficking, signaling, and transformation by latent membrane protein 1. J Virol (2007) 0.90
Comprehensive profiling of Epstein-Barr virus-encoded miRNA species associated with specific latency types in tumor cells. Virol J (2013) 0.90
Epstein-Barr virus infection and sporadic breast cancer risk: a meta-analysis. PLoS One (2012) 0.89
Targeting the autophagy pathway for cancer chemoprevention. Curr Opin Cell Biol (2010) 0.87
Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence. Proc Biol Sci (2009) 0.86
Phosphorylation sites of Epstein-Barr virus EBNA1 regulate its function. J Gen Virol (2009) 0.86
Activation of the Epstein-Barr virus lytic cycle by the latex of the plant Euphorbia tirucalli. Br J Cancer (2003) 0.85
Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol Cancer (2010) 0.85
Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Cancer Sci (2014) 0.84
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
The first endogenous herpesvirus, identified in the tarsier genome, and novel sequences from primate rhadinoviruses and lymphocryptoviruses. PLoS Genet (2014) 0.83
Evidence of Epstein-Barr virus association with gastric cancer and non-atrophic gastritis. Viruses (2014) 0.83
Epstein-Barr virus can establish infection in the absence of a classical memory B-cell population. J Virol (2005) 0.82
Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology. J Transl Med (2009) 0.81
Concluding overview: looking back, looking forward. Philos Trans R Soc Lond B Biol Sci (2001) 0.81
C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog (2011) 0.81
Antigen-binding properties of monoclonal antibodies reactive with EBNA1 and use in immunoaffinity chromatography. PLoS One (2009) 0.81
Detection of the Epstein-Barr virus (EBV) by in situ hybridization as definitive diagnosis of hairy leukoplakia. Head Neck Pathol (2008) 0.81
Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS One (2011) 0.80
A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal. Adv Hematol (2011) 0.80
Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression. PLoS One (2012) 0.80
The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1. Am J Blood Res (2013) 0.80
Evidence of an oncogenic gammaherpesvirus in domestic dogs. Virology (2012) 0.80
Crystallization and preliminary X-ray characterization of Epstein-Barr virus BHRF1 in complex with a benzoylurea peptidomimetic. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.79
Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res (2014) 0.79
Induction of Epstein-Barr virus (EBV) lytic cycle in vitro causes lipid peroxidation, protein oxidation and DNA damage in lymphoblastoid B cell lines. Lipids Health Dis (2011) 0.78
Incidence of Infectious Mononucleosis in Universities and U.S. Military Settings. J Diagn Tech Biomed Anal (2014) 0.78
Large-scale Epstein-Barr virus EBNA1 protein purification. Protein Expr Purif (2008) 0.76
EBV Chronic Infections. Mediterr J Hematol Infect Dis (2010) 0.76
Identification and functional comparison of seven-transmembrane G-protein-coupled BILF1 receptors in recently discovered nonhuman primate lymphocryptoviruses. J Virol (2014) 0.76
The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based survey. Infect Agent Cancer (2014) 0.76
Maternal and perinatal factors associated with hospitalised infectious mononucleosis in children, adolescents and young adults: record linkage study. BMC Infect Dis (2011) 0.75
Immunotherapy against cancer-related viruses. Cell Res (2016) 0.75
Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant. Rev Bras Hematol Hemoter (2011) 0.75
A possible link between the Epstein-Barr virus infection and autoimmune thyroid disorders. Cent Eur J Immunol (2016) 0.75
Etiopathogenesis of Burkitt's lymphoma: a lesson from a BL-like in CD1 mouse immune to Plasmodium yoelii yoelii. Infect Agent Cancer (2011) 0.75
Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells. Oncotarget (2016) 0.75
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
Germinal centers. Annu Rev Immunol (1994) 10.85
A sarcoma involving the jaws in African children. Br J Surg (1958) 10.60
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 6.38
Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer (1968) 6.29
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell (1986) 5.13
Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med (1985) 4.78
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 4.47
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A (1966) 3.56
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell (1995) 3.17
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol (1992) 2.95
Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol (1987) 2.74
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol (1973) 2.71
T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med (1988) 2.63
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 2.60
Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet (1982) 2.58
Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol (1997) 2.53
Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A (1994) 2.49
The pathogenesis of Burkitt's lymphoma. Adv Cancer Res (1990) 2.35
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer (1990) 2.28
Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med (1999) 2.27
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med (1989) 2.25
Evidence for a malaria mitogen in human malaria. Nature (1975) 2.25
The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer (1987) 2.16
Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation (1990) 2.13
Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus. J Natl Cancer Inst (1969) 1.95
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature (1990) 1.87
Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol (1999) 1.86
Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J (1996) 1.80
Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer (1989) 1.76
T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature (1985) 1.69
A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci (1999) 1.64
A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet (1986) 1.61
Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet (1980) 1.60
Episomal and integrated copies of Epstein-Barr virus coexist in Burkitt lymphoma cell lines. J Virol (1993) 1.56
Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant (1992) 1.54
Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet (1999) 1.46
EB virus induction is associated with B-cell maturation. Immunology (1986) 1.45
Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol (1995) 1.43
Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. Int J Cancer (1998) 1.41
Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res (1991) 1.36
Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet (1991) 1.35
Epidemiology of Hodgkin's disease. Semin Oncol (1980) 1.33
Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol (1992) 1.27
Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood (1999) 1.24
Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. Blood (1997) 1.23
Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol (1995) 1.20
The biology of the SCID mutation. Immunol Today (1989) 1.19
Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med (1991) 1.18
An Epstein-Barr virus-associated superantigen. J Exp Med (1996) 1.17
X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol (1999) 1.15
Infection of human thymocytes by Epstein-Barr virus. J Exp Med (1991) 1.15
Excretion of the Epstein-Barr virus from the genital tract of men. J Infect Dis (1991) 1.10
Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21). J Virol (1988) 1.08
Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol (1995) 1.05
The ins and outs of EBV infection. Trends Microbiol (2000) 1.05
The role of EBV in post-transplant malignancies: a review. J Clin Pathol (2000) 1.02
Patterns of cytokine gene expression in infectious mononucleosis. Blood (1994) 0.99
A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation (1997) 0.97
Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol (1996) 0.96
Epstein-Barr virus gene expression and epithelial cell differentiation in oral hairy leukoplakia. Am J Pathol (1991) 0.95
Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene (1997) 0.92
T-cell memory: lessons from Epstein-Barr virus infection in man. Philos Trans R Soc Lond B Biol Sci (2000) 0.92
Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br J Haematol (2000) 0.89
The gene defective in X-linked lymphoproliferative disease controls T cell dependent immune surveillance against Epstein-Barr virus. Curr Opin Immunol (2000) 0.87
Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol (1998) 0.83
Epstein-Barr virus associated Burkitt lymphoma in a heart transplant recipient. Transplantation (1996) 0.78